In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD (academic clinical lecturer in rheumatology, University of Leeds), and Rihards Buss, MD (consultant rheumatologist, Freeman Hospital, Newcastle), record a post-EULAR 2026 debrief, working through the abstracts each identified as the meeting's most consequential. The conversation spans cellular therapies in autoimmune disease, proteomic biomarkers for treatment selection in RA, a landmark head-to-head trial in psoriatic arthritis, evolving classification criteria for axial spondyloarthritis, and the first phase III randomized controlled trial of a JAK inhibitor in polymyalgia rheumatica.

Studies featured in this episode include:

• AB-101 Allogeneic NK Cell Therapy in Rheumatologic Diseases (LB0003)
• CARLYSLE: Obe-Cel CAR T in Severe Refractory SLE (OP0341)
• Ex Vivo Proteomic Signatures of JAK and TNF Inhibitors Predict Treatment Response in RA (OP048)
• BE BOLD: Bimekizumab vs Risankizumab in PsA (LB0001)
• 2025 ASAS-SPARTAN Revised AxSpA Classification Criteria (OP0236, OP0239, POS0190, POS1341)
• JAK-SPARE: Baricitinib in Early Polymyalgia Rheumatica (LB0005)

Could hepatitis B finally have a finite treatment option? Tatyana Kushner, MD, joins hosts Nancy Reau, MD, and Kimberly Brown, MD, to break down the phase 3 B-Well data for bepirovirsen, the first agent to hit functional cure as a primary endpoint in chronic hepatitis B.

The conversation covers the phase 3 B-Well 1 and B-Well 2 results, published in the New England Journal of Medicine and presented at EASL 2026, and why quantitative HBsAg testing is becoming essential to patient selection ahead of a potential approval. Kushner, Reau, and Brown also work through what functional cure actually means for patients, how it compares to spontaneous HBsAg loss, and what dosing and monitoring are likely to look like given signals for ALT elevation and renal effects seen in the trials. They discuss which patients are unlikely to be candidates, including those with cirrhosis or decompensated liver disease, and close with a look at what an approval could mean for hepatitis B screening rates and referral patterns between primary care and specialty hepatology.

Bepirovirsen is not yet FDA approved. The FDA has accepted the New Drug Application for priority review, with a PDUFA goal date of October 26, 2026.

For more: https://www.hcplive.com/view/liver-lineup-bepirovirsen-and-the-push-toward-functional-cure-in-hepatitis-b

In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Kimberly Brown, MD (Henry Ford Hospital), and Nancy Reau, MD (Rush University Medical Center), are joined by Tatyana Kushner, MD (Weill Cornell Medicine), to discuss hepatitis delta virus (HDV).

Topics covered:
Why fewer than 10% of HBsAg-positive patients have ever been tested for HDV — and why that needs to change
The diagnostic cascade from HDV antibody to HDV RNA, and barriers to reflex testing implementation
The recent FDA approval of bulevirtide (Livdelzi) for chronic HDV infection, including dosing, administration, and the combination vs. monotherapy question
10 mg vs. 2 mg dose considerations and off-treatment response data
Phase 3 pipeline

For more: https://www.hcplive.com/view/liver-lineup-hdv-diagnosis-bulevirtide-and-the-delta-pipeline